Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme

International Journal of Epidemiology

Volumn 36, Issue 5, 2007, Pages 969-976

  Mcgowan, Catherine C ^a   Cahn, Pedro ^b   Gotuzzo, Eduardo ^c   Padgett, Denis ^d   Pape, Jean W ^e   Wolff, Marcelo ^f   Schechter, Mauro ^g   Masys, Daniel R ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FUNDACIÓN HUÉSPED   (Argentina)

^c INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^d NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^e Centers Institute of Infectious Diseases and Reproductive Health   (Haïti)

^f UNIVERSITY OF CHILE   (Chile)

^g FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COHORT ANALYSIS; DATABASE; EPIDEMIOLOGY; HUMAN IMMUNODEFICIENCY VIRUS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COHORT ANALYSIS; DRUG CHOICE; DRUG EFFICACY; FOLLOW UP; FUNDING; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ACCESS; HEALTH EDUCATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INTERNATIONAL COOPERATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY CONTROL; SOCIAL SUPPORT; STATISTICAL ANALYSIS; SUPERINFECTION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOMEDICAL RESEARCH; CARIBBEAN REGION; CENTRAL AMERICA; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; PATIENT DROPOUTS; PROGRAM EVALUATION; SOUTH AMERICA;

ATLANTIC ISLANDS; ATLANTIC OCEAN; CARIBBEAN ISLANDS; CENTRAL AMERICA; SOUTH AMERICA;

EID: 35548955556     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dym073     Document Type: Article

References (24)

1. Mellors JW, Munoz A. Giorgi JV et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
2. Bacon MC, von Wyl V, Alden C et al. The Women's Interagency HIV Study: An observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005;12:1013-39.
3. Gebo KA, Fleishman JA, Conviser R et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005;38:96-103.
4. Phillips AN, Grabar S, Tassie JM et al. Use of observational databases to evaluate the effectiveness of intiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials. AIDS 1999;13:2075-82.
5. Egger M, May M, Cherie G et al. Prognosis of HIV-1 -infected -patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002;360:119-29.
6. May MT, Sterne JA, Costagliola. D et al. The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: A collaborative analysis. Lancet 2006; 368:451-58.
7. Coetzee D. Hildebrand K, Boulle A et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004;18:887-95.
8. Severe P, Leger P, Charles M et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. New Engl J Med 2005;353 2325-34.
9. Wolff MJ, Beltran CJ, Vasquez P et al. The Chilean AIDS Cohort: A model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country organization and preliminary results. J Acquir Immune Defic Syndr 2005;40 551-57.
10. Tuboi SH, Harrisch LH, Sprinz B, Albernaz RK, Schechter M. Predictor of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir immune Defic Syndr 2005;40:324-28.
11. Zhou J, Kumarasamy N, Ditangco R et al. The TREAT Asia HIV Observational Database: Baseline and retrospective data. J. Acquir Immun Defic Syndr 2005;38:174-79.
12. Dabis F, Balestre E, Braitstein P et al. The Antiretroviral Therapy in Lower Income Countries (ART-UNC) Study Group. Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts. Int J Epidemiol 2005;34:979-86.
13. Braitstein P, Brinkhof MW, Dabis F et al. The Antiretroviral Therapy in Lower income Countries (ART-LINC) Collaboration and ART Cohort Collaboration (ART-CC) Groups. Mortality of HIV1-infected patients in the first year of antiretroviral therapy: Comparison between low-income and high-income countries. Lancet 2006;367:817-24.
14. Tuboi SH, Brinkhof MG, Egger M et al. Discordant responses to potent antiretroviral treatment in previously naive HIV-1 infected adults initiating treatment in resource-constrained countries. J Acquir Immune Defic Syndrk 2007;45:52-9.
15. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach, 2006. Available at: http://www.who.int/pub/guidelines/ artadultguidelines.pdf (Accessed February, 2007).
16. Duda SN, Cushman C, Masys DR. An XML model of an enhanced data dictionary to facilitate the exchange of clinical research data in international studies. MEDINFO, 2007 Brisbane Proceedings. Int J Medical Informatics. Suppl. In press.
17. Greenland S. Multiple-bias modelling for analysis of observational data. J R Stat Soc Ser A 2005;168:267-306.
18. Huang J, Brunelle R. A nonparametric method for combining multilaboratory data. Drug Inf J 2002;36:395-406.
19. Shepherd BE, Rossini AJ, Soto RJ, De Rivera IL, Mullins JI. Sampling designs for HIV molecular epidemiology with application to Honduras. AIDS Res Hum Retroviruses 2005;21:907-14.
20. Anglaret X, Toure S, Gourvellec G et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 2004;35:320-23.
21. United States Department of Health and Human Services, Office for Human Research Protections. Federalwide Assurance (FWA) for the protection of human subjects. Available at: http://www.hhs.gov/ohrp/humansubjects/ assurance/flasurt.htm (Accessed February, 2007).
22. Fitzgerald DW, Marotte C, Verdier RI, Johnson WD, Pape JW. Comprehension during informed consent in a less-developed country. Lancet 2002;360:1301-2.
23. Fitzgerald DW, Pape JW, Wasserheit JN, Counts GW, Corey L. Provision of treatment in HIV-1 vaccine trials in developing countries. Lancet 2003;362:993-94.
24. Gange SJ, Kitahata MK Saag MS et al. Cohort Profile: The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007;36:294-301.